|Articles|May 1, 2004

Some Insurers Still Reluctant to Pay for New Biologic Drugs

Maui, Hawaii - Some insurers are reluctant to pay for the new biologic drugs for psoriasis, despite the approval of two of the drugs by the U.S. Food and Drug Administration, according to William Abramovits, M.D.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME